Health & bio
Veppanu Approved for ER+ Breast Cancer
On May 1st, the FDA approved Veppanu (bepedegertrant) for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations.
Primary sources · 1
On May 1st, the FDA approved Veppanu (bepedegertrant) for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.